Oncothyreon’s Cancer Vaccine Well-Tolerated in Long Use

xconomy.com -- Oncothyreon, the Seattle-based developer of cancer treatments, said today its Stimuvax therapy showed a long-lasting response and was well-tolerated in a long-term follow-up study.